Factors Associated with Rivaroxaban Prescribing in Specialist Care Setting: Interim Results from the Rivaroxaban Observational Safety Evaluation (ROSE) Study

被引：0
|
作者：
Layton, Deborah [1 ,2 ]
Evans, Alison [1 ,2 ]
Davies, Miranda [1 ,2 ]
Osborne, Vicki [1 ,2 ]
Shakir, Saad A. W. [1 ,2 ]
机构：
[1] Drug Safety Res Unit, Southampton, Hants, England
[2] Univ Portsmoth, Portsmouth, Hants, England
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2016年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
337
引用
收藏
页码：197 / 198
页数：2
相关论文
共 50 条
  • [1] Characteristics of patients initiated on a reduced dose of rivaroxaban for atrial fibrillation (AF)-Results from the ROSE (Rivaroxaban Observational Safety Evaluation) study
    Davies, Miranda
    Evans, Alison
    Coukan, Flavien
    Wise, Lesley
    Shakir, Saad
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 458 - 459
  • [2] Utilisation and safety of rivaroxaban for acute coronary syndrome (ACS) in secondary care in the UK: Results from the rivaroxaban observational safety evaluation post ACS (ROSE-ACS) study
    Evans, Alison
    Dhanda, Sandeep
    Osborne, Vicki
    Roy, Debabrata
    Shakir, Saad
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 469 - 469
  • [3] Incidence of major and clinically relevant non-major (CRNM) bleeding in patients prescribed rivaroxaban in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
    Evans, Alison
    Davies, Miranda
    Wise, Lesley
    Shakir, Saad
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 456 - 457
  • [4] Cohort Characteristics and Determinants of Prescribing Rivaroxaban in Primary Care in England: Interim Results from a Post Authorisation Safety Study (PASS)
    Dhanda, Sandeep
    Davies, Miranda
    Layton, Deborah
    Osborne, Vicki
    Shakir, Saad A. W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 198 - 198
  • [5] Assessment of initiation dose in patients prescribed rivaroxaban for stroke prevention in non-valvular AF (SPAF) and chronic kidney disease-Results from the ROSE (Rivaroxaban Observational Safety Evaluation) study
    Davies, Miranda
    Evans, Alison
    Coukan, Flavien
    Wise, Lesley
    Shakir, Saad
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 459 - 459
  • [6] Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
    Evans, Alison
    Davies, Miranda
    Osborne, Vicki
    Roy, Debabrata
    Shakir, Saad
    PLOS ONE, 2020, 15 (10):
  • [7] Utilisation and Baseline Risk of Bleeding in Patients Prescribed Rivaroxaban: Interim Results from a Post-Marketing Observational Cohort Study
    Osborne, Vicki
    Davies, Miranda
    Layton, Deborah
    Shakir, Saad A. W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 76 - 76
  • [8] Characteristics of Patients Started on a Reduced Dose of Rivaroxaban for Atrial Fibrillation-Results from the ROSE Study
    Davies, M.
    Evans, A.
    Coukan, F.
    Wise, L.
    Shakir, S.
    DRUG SAFETY, 2018, 41 (11) : 1153 - 1153
  • [9] RIVAROXABAN FOR THROMBOSIS IN PEDIATRIC PATIENTS: A RETROSPECTIVE OBSERVATIONAL STUDY FROM THE LOW/MIDDLE INCOME SETTING.
    Mehmood, Aimen
    Moiz, Bushra
    Fadoo, Zehra
    Belgaumi, Asim
    Mushtaq, Naureen
    Altaf, Sadaf
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E73 - E74
  • [10] Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study
    Amarenco, Pierre
    Haas, Sylvia
    Hess, Susanne
    Kirchhof, Paulus
    Lambelet, Marc
    Bach, Miriam
    Turpie, Alexander G. G.
    Camm, A. John
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (02) : 70 - 79
12345